摘要
背景与目的:由于肿瘤存在异质性,患同种肿瘤的不同患者对化疗药物具有不同对敏感性,研究显示,近年发展起来的ATP肿瘤体外药敏试验(ATP-TCA)对肿瘤患者对个体化治疗具有较大的指导价值。本研究探讨ATP-肿瘤体外药敏试验(ATP-TCA)应用于卵巢癌化疗的可行性,比较PEOC手术标本对5种化疗药物的体外敏感性。方法:采用ATP-TCA法对24例原发上皮性卵巢癌患者手术切除的新鲜癌组织进行体外药物敏感性测定,分别检测对紫杉醇(泰素)、顺铂、吉西他滨(健择)、多柔比星(阿霉素)、拓扑替康5种化疗药物的敏感性。结果:24例上皮性卵巢癌手术标本中,ATP-TCA可评价率95.83%,所测标本对药物的体外敏感率依次为泰素91.30%,吉西他滨86.96%、多柔比星65.22%、拓扑替康47.83%、顺铂21.74%。按ATP-TCA药敏结果进行个体化化疗,近期疗效较好,肿瘤缓解率高。结论:ATP-TCA是一种简便、敏感、标准化的方法,在卵巢癌临床化疗筛选用药方面值得进一步研究。
Background and purpose： Because of the heterogeneity of cancers, different patients with the same kind of cancer have different sensitivity for cytotoxic drugs. Newly developed ATP chemosensitivity assays（ATP-TCA） offer the opportunity for individualized therapy and have shown promising results compared to standard regimens. We explored the feasibility of the ATP- Tumor Chemosensitivity Assay （ATP-TCA） applied in the treatment of ovarian cancer with chemotherapy, and evaluate the in vitro sensitivity of fresh specimens of ovarian cancer to five cytotoxic drugs. Methods： ATP-TCA was used to detect the sensitivity rate of 24 fresh specimens of ovarian cancer to five cytotoxic drugs as follows： paclitaxel （TAX）, gemcitabine（GEM）, doxorubicin（ADM）, topotecan （TPT）, cisplatin（ DDP）. Results： 23 of 24 specimens（95.83% ） can be evaluated by ATP-TCA, the sensitive rates of ATP-TCA was 91.30% for TAX, 86.96% for GEM, 65.22% for ADM, 47.83% for TPT and 21.74% for DDP, respectively. Conclusions： ATP-TCA was a sensitive,reliable and standardized method for the evaluation of tumor chemosensitivity, it ts worthwhile to investigate further for the application screening anticancer agents in chemotherapy of ovarian cancer.
出处
《中国癌症杂志》
CAS
CSCD
2006年第2期85-88,共4页
China Oncology
基金
江西省科技厅重点计划(2003A05)
